Research Topics
Species | HARRY BEARSummaryAffiliation: Virginia Commonwealth University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Tumor escape and progression of HER-2/neu negative breast cancer under immune pressureMaciej Kmieciak
Department of Microbiology and Immunology, Virginia Commonwealth University Massey Cancer Center, Richmond, 23298, USA
J Transl Med 9:35. 2011..These data suggest that patients with HER-2/neu negative breast cancer might have had HER-2/neu positive premalignant lesions in the past that progressed to HER-2/neu negative breast cancer under HER-2/neu-specific immune pressure...- Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor functionMaciej Kmieciak
Department of Microbiology and Immunology, Virginia Commonwealth University Massey Cancer Center, Richmond, USA
J Transl Med 7:89. 2009..While some reports have shown that human Foxp3+ T cells had no regulatory function others have shown their role in the inhibition of T cell proliferation... - Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinomaCatriona H T Miller
Department of Microbiology and Immunology, Virginia Commonwealth University s Medical College of Virginia, Richmond, Virginia, USA
BMC Immunol 11:54. 2010..We hypothesized that tumor regression is mediated by a subset of the transferred T lymphocytes, which selectively infiltrate the tumor draining lymph nodes and proliferate in vivo... - Bevacizumab added to neoadjuvant chemotherapy for breast cancerHarry D Bear
Medical College of Virginia School of Medicine and the Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298 0011, USA
N Engl J Med 366:310-20. 2012.... - Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapyHarry D Bear
Division of Surgical Oncology, Department of Surgery, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298 0011, USA
Surg Oncol Clin N Am 19:607-26. 2010..This will accelerate better understanding of breast cancer biology and progress toward improved and more individualized therapy... - Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27Harry D Bear
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
J Clin Oncol 24:2019-27. 2006..This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS)... - Walter Lawrence, Jr.: a tribute to a surgical oncologist. "Been there, done that"Harry D Bear
Division of Surgical Oncology, Virginia Commonwealth University and the Massey Cancer Center, Richmond, Virginia 23298-0011, USA
J Surg Oncol 90:109-12. 2005 - Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Priya Rastogi
University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
J Clin Oncol 26:778-85. 2008..Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS... - Tumor bed boost omission after negative re-excision in breast-conservation treatmentDouglas W Arthur
Deparment of Radiation Oncology, Virginia Commonwealth University, Medical College of Virginia Campus, 401 College Street, Box 58, Richmond, Virginia 23298, USA
Ann Surg Oncol 13:794-801. 2006..We evaluated the necessity of a tumor bed boost after whole-breast radiotherapy for early-stage breast cancer after breast-conserving surgery and negative re-excision... - Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27Eleftherios P Mamounas
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
J Clin Oncol 23:2694-702. 2005..Experience with sentinel node biopsy (SNB) after neoadjuvant chemotherapy is limited. We examined the feasibility and accuracy of this procedure within a randomized trial in patients treated with neoadjuvant chemotherapy... - Breast conservation therapy rates are no different in medically indigent versus insured patients with early stage breast cancerMaryam Parviz
Division of Surgical Oncology, Virginia Commonwealth University Health Systems, Richmond, Virginia 23298-0011, USA
J Surg Oncol 84:57-62. 2003..Distance of <40 miles to a radiation therapy facility, Stage I disease, and diagnosis after 1995 were factors associated with higher BCT rates... - Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questionsSharon Goble
Department of Medicine, Division of Hematology/Oncology, Virginia Commonwealth University's Medical College of Virginia, P.O. Box 980230, VCUHS, Richmond, VA 23298-0230, USA
Surg Clin North Am 83:943-71. 2003..Clearly, much work remains to be done in this area of research on breast cancer therapy... - The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27Harry D Bear
Virginia Commonwealth University, Medical College of Virginia School of Medicine, Richmond, VA, USA
J Clin Oncol 21:4165-74. 2003.... - Imaging multidrug resistance with 4-[18F]fluoropaclitaxelKaren A Kurdziel
Department of Radiology, Virginia Commonwealth University, Richmond, VA, USA
Nucl Med Biol 34:823-31. 2007..FPAC PET imaging shows promise for the noninvasive pretreatment identification of MDR-expressing tumors. While much additional work is needed, this work represents a step toward image-guided personalized medicine... - Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experienceDouglas W Arthur
Department of Radiation Oncology, Virginia Commonwealth University Medical College of Virginia Campus, Richmond, VA, USA
Int J Radiat Oncol Biol Phys 56:681-9. 2003..In a cohort of patients who received low-dose-rate (LDR) or high-dose-rate (HDR) PBB after lumpectomy, the clinical characteristics and treatment parameters were analyzed to identify predictors for an unfavorable cosmetic outcome... - Effects of surgical excision on survival of patients with stage IV breast cancerAnna M Leung
Department of Surgery, Massey Cancer Center, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, Virginia 23298 0568, USA
J Surg Res 161:83-8. 2010..Non-palliative resection of the primary tumor in stage IV breast cancer is controversial. Our aim was to determine whether surgery improves survival in stage IV patients... - Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor modelMaryam Parviz
Department of Surgery and the Massey Cancer Center, Virginia Commonwealth University's Medical College of Virginia, Richmond, Virginia 23298-0011, USA
Cancer Immunol Immunother 52:739-50. 2003..The response to tumor cell vaccine can be amplified by ex vivo pharmacologic activation of sensitized T cells, which can then cure an established, weakly immunogenic and highly aggressive tumor that was resistant to vaccination alone... - IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivoEsther Cha
Department of Physiology and Biophysics, Virginia Commonwealth University s Medical College of Virginia, Richmond, VA, USA
Breast Cancer Res Treat 122:359-69. 2010..Activation of tumor antigen-sensitized T cells with B/I and culture in IL-7 + IL-15 is a promising modification of standard regimens for production of T cells for use in AIT of cancer... - Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasisMehran Habibi
Department of Microbiology and Immunology, VCU School of Medicine, Massey Cancer Center, 401 College Street, Box 980035, Richmond, VA 23298, USA
Breast Cancer Res Treat 114:423-31. 2009..We showed for the first time that unlike RFA alone, RFA combined with the administration of intralesional IL-7 and IL-15 (after RFA), induced immune responses to tumors, inhibited tumor development and lung metastasis, and reduced MDSC... - Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumorsAndrea Worschech
Department of Microbiology and Immunology, Virginia Commonwealth University School of Medicine, Massey Cancer Center, Richmond, VA 23298, USA
Cancer Res 68:2436-46. 2008..These data provide a road map for the identification of novel biomarkers of immune responsiveness in clinical trials... - Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing miceHanh K Le
Department of Physiology and Biophysics, Virginia Commonwealth University s Medical College of Virginia, Richmond, Virginia, USA
Int Immunopharmacol 9:900-9. 2009..This study provides support for direct inhibition of MDSCs and direct reduction of tumor burden by GEM in 4T1 tumor-bearing mice. GEM treatment of mice with advanced tumors improves T cell function and growth in vitro... - Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytesCynthia S Chin
Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University Medical College of Virginia, Richmond 23298, USA
Int Immunol 16:1283-94. 2004..CD62Llow cells are preferentially activated by B/I, leading to a highly effective anti-tumor T cell population... - GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cellsJohanna K Morales
Department of Microbiology and Immunology, Virginia Commonwealth University School of Medicine, Massey Cancer Center, Box 980035, 401 College St, Richmond, VA 23298, USA
Breast Cancer Res Treat 123:39-49. 2010.... - Measuring circulating tumor cells as a surrogate end point for adjuvant therapy of breast cancer: what do they mean and what should we do about them?Harry D Bear
J Clin Oncol 26:1195-7. 2008 - Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conferenceThomas A Buchholz
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcolmbe Blvd, Unit 1202, Houston, TX 77030, USA
J Clin Oncol 26:791-7. 2008..To review the state of the science with respect to diagnostic imaging and locoregional therapy for patients with breast cancer receiving preoperative chemotherapy... - Taking action on the volume-quality relationship: how long can we hide our heads in the colostomy bag?Thomas J Smith
J Natl Cancer Inst 95:695-7. 2003 - Sentinel node micrometastases and non-sentinel nodes in breast cancer: how much do we need to know?Harry D Bear
J Clin Oncol 24:1788-90. 2006 - Reaping the harvest from neoadjuvant therapy for breast cancer: reducing morbidity with sentinel lymph node biopsyHarry D Bear
J Surg Oncol 95:527-9. 2007 - Completion axillary lymph node dissection for breast cancer: immediate versus delayed versus noneHarry D Bear
J Clin Oncol 26:3483-4. 2008 - Earlier chemotherapy for breast cancer: perhaps too late but still usefulHarry D Bear
Ann Surg Oncol 10:334-5. 2003
Research Grants
- EXPANSION OF ANTITUMOR T CELLS FROM TUMOR-BEARING HOSTSHARRY BEAR; Fiscal Year: 2000....
- EXPANSION OF ANTI-TUMOR T CELLS FROM TUMOR-BEARING HOSTSHARRY BEAR; Fiscal Year: 1993..The proposed studies should lead to a clearer. understanding of tumor-specific CTL activation, regulation and growth and to more rational and more effective strategies for clinical adoptive immunotherapy of cancer...
- EXPANSION OF ANTI-TUMOR T CELLS FROM TUMOR-BEARING HOSTSHARRY BEAR; Fiscal Year: 1990....
- Expansion of Anti Tumor T Cells from Tumor Bearing HostsHARRY BEAR; Fiscal Year: 2004..These studies will increase our understanding of how to manipulate immune responses to tumor antigens and of basic T lymphocyte biology. ..